Document Detail

Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
MedLine Citation:
PMID:  16462543     Owner:  NLM     Status:  MEDLINE    
We report the case of a 45-year-old man with HCV treated with pegylated interferon-alpha/ribavirin, in whom fatal cardiomyopathy occurred. Cardiomyopathy is a rare complication of high dose of standard interferon but has never been reported with pegylated interferon. The relationship between pegylated interferon-alpha/ribavirin and the development of cardiomyopathy is highly probable for the following reasons: (1) a cardiologist consultation with specific investigations had been performed before treatment excluding a pre-existing cardiomyopathy; (2) symptoms of advanced dilated cardiomyopathy appeared immediately after the end of treatment; (3) other causes of cardiomyopathy have been ruled out. In all except one of the 21 reported cases with standard interferon, cardiomyopathy was reversible. In our patient, fatal cardiomyopathy occurred with a usual dose of pegylated interferon-alpha. Clinicians should be aware of this potential complication when evaluating the ratio benefit/risk of treatment in patients with chronic hepatitis C infection.
Bertrand Condat; Tarik Asselah; David Zanditenas; Bertrande Estampes; Ariel Cohen; Dermot O'Toole; Joëlle Bonnet; Yann Ngo; Patrick Marcellin; Martine Blazquez
Related Documents :
8562943 - Leukemia-associated changes identified by quantitative flow cytometry. iv. cd34 overexp...
1945823 - Bleeding in acute promyelocytic leukemia (apl): fibrinolysis or defibrination?
23812963 - Rhabdoid glioblastoma: a recently recognized subtype of glioblastoma.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  18     ISSN:  0954-691X     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-07     Completed Date:  2006-11-14     Revised Date:  2009-10-16    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  287-9     Citation Subset:  IM    
Service d'hépato-gastroentérologie, Hôpital Saint-Camille, Bry sur Marne, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  adverse effects*
Cardiomyopathy, Dilated / chemically induced*
Drug Administration Schedule
Drug Therapy, Combination
Fatal Outcome
Hepatitis C, Chronic / drug therapy*
Interferon Alfa-2a / administration & dosage,  adverse effects*
Middle Aged
Polyethylene Glycols / administration & dosage,  adverse effects*
Ribavirin / administration & dosage,  adverse effects*
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inter-observer variations on interpretation of capsule endoscopies.
Next Document:  Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis...